Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of silicon phthalocyanine 4 and
photodynamic therapy in treating patients with stage IA-IIA cutaneous T-cell non-Hodgkin
lymphoma. Photodynamic therapy (PDT) uses a drug, silicon phthalocyanine 4, that becomes
active when it is exposed to a certain kind of light. When the drug is active, cancer cells
are killed. This may be effective against cutaneous T-cell non-Hodgkin lymphoma.
Funding Source - FDA OOPD